Andrew R. Hoffman

Publications

• Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR. Ann Intern Med. 2007; 146 (2): 104-15
• CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW, Cherry AM, Hoffman AR. Science. 2006; 312 (5771): 269-72
• A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T, Hoffman AR. J Clin Invest. 2003; 111 (2): 265-73
• Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. Vu TH, Hoffman AR. Nat Genet. 1997; 17 (1): 12-3
• Promoter-specific imprinting of the human insulin-like growth factor-II gene. Vu TH, Hoffman AR. Nature. 1994; 371 (6499): 714-7
• Successful long-term treatment of Cushing disease with mifepristone (RU486). Basina M, Liu H, Hoffman AR, Feldman D. Endocr Pract. 2012 Sep-Oct; 18 (5): e114-20
• Long-term surveillance of growth hormone therapy. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P, Savage MO, Wit JM. J Clin Endocrinol Metab. 2012; 97 (1): 68-72
• Thyroid function and mortality in older men: a prospective study. Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBLanc ES, Hoffman AR, Orwoll E, Fink HA, Barrett-Connor E, Bauer DC. J Clin Endocrinol Metab. 2012; 97 (3): 862-70
• Higher testosterone levels are associated with less loss of lean body mass in older men. LeBlanc ES, Wang PY, Lee CG, Barrett-Connor E, Cauley JA, Hoffman AR, Laughlin GA, Marshall LM, Orwoll ES. J Clin Endocrinol Metab. 2011; 96 (12): 3855-63
• IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF, Werther GA, Russo VC. Endocrinology. 2011; 152 (9): 3332-42
• Mortality risk in older men associated with changes in weight, lean mass, and fat mass. Lee CG, Boyko EJ, Nielson CM, Stefanick ML, Bauer DC, Hoffman AR, Dam TT, Lapidus JA, Cawthon PM, Ensrud KE, Orwoll ES. J Am Geriatr Soc. 2011; 59 (2): 233-40
• Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Vu TH, Nguyen AH, Hoffman AR. Hum Mol Genet. 2010; 19 (5): 901-19
• A complex deoxyribonucleic acid looping configuration associated with the silencing of the maternal Igf2 allele. Qiu X, Vu TH, Lu Q, Ling JQ, Li T, Hou A, Wang SK, Chen HL, Hu JF, Hoffman AR. Mol Endocrinol. 2008; 22 (6): 1476-88
• CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Li T, Hu JF, Qiu X, Ling J, Chen H, Wang S, Hou A, Vu TH, Hoffman AR. Mol Cell Biol. 2008; 28 (20): 6473-82
• Systematic review: the effects of growth hormone on athletic performance. Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM, Hoffman AR. Ann Intern Med. 2008; 148 (10): 747-58
• Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B. J Clin Endocrinol Metab. 2005; 90 (12): 6431-40
• Activating and silencing histone modifications form independent allelic switch regions in the imprinted Gnas gene. Li T, Vu TH, Ulaner GA, Yang Y, Hu JF, Hoffman AR. Hum Mol Genet. 2004; 13 (7): 741-50
• Promoter-restricted histone code, not the differentially methylated DNA regions or antisense transcripts, marks the imprinting status of IGF2R in human and mouse. Vu TH, Li T, Hoffman AR. Hum Mol Genet. 2004; 13 (19): 2233-45
• An imprinted PEG1/MEST antisense expressed predominantly in human testis and in mature spermatozoa. Li T, Vu TH, Lee KO, Yang Y, Nguyen CV, Bui HQ, Zeng ZL, Nguyen BT, Hu JF, Murphy SK, Jirtle RL, Hoffman AR. J Biol Chem. 2002; 277 (16): 13518-27
• One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, Friedman L, Yesavage J, Matthias D, Lee S, Marcus R, Hoffman AR. J Clin Endocrinol Metab. 2001; 86 (4): 1496-503